Treatment of lymphomas using an ezh2 inhibitor
TW202637142APending Publication Date: 2026-09-16TREELINE BIOSCIENCES INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114138191
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-02-28
- Filing Date
- 2025-10-02
- Publication Date
- 2026-09-16
Abstract
This article provides a method for treating an individual with lymphoma (e.g., peripheral T-cell lymphoma (PTCL) such as intranodal Tfh-cell lymphoma) and / or cutaneous T-cell lymphoma (CTCL)) by administering compound A or a pharmaceutically acceptable salt thereof to the individual. In some cases, the lymphoma is BCL6 positive. In some cases, the lymphoma is relapsed or refractory. In some cases, the individual is receiving treatment for the first time (i.e., has not previously received treatment).
Need to check novelty before this filing date? Find Prior Art